Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

We conduct this study to investigate the efficacy of triple therapy (high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy regimens (high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor) and whether it reduces the risk of poor pulmonary prognosis in patients with moderate to high risk anti-MDA5+ DM.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Criteria

Inclusion Criteria:

Adult patients meet the diagnostic criteria for dermatomyositis of Bohan and Peter.

Anti-MDA5 Antibody-positive.

Exclusion Criteria:

Complicated with other connective tissue diseases. Complicated with cardiovascular and respiratory disease caused by other reasons.

Interstitial lung disease caused by environment and drugs. Patients with key research missing data or without informed consent.